Clinical Trial Update: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating furmonertinib combined with anlotinib as first-line therapy for EGFR mutation-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Furmonertinib (furmonertinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: UNKNOWN